Triple-negative breast cancer: Disease entity or title of convenience?

Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni

Research output: Contribution to journalArticle

Abstract

This Review outlines the understanding and management of triple-negative breast cancer (TNBC). TNBC shares morphological and genetic abnormalities with basal-like breast cancer (BLBC), a subgroup of breast cancer defined by gene-expression profiling. However, TNBC and BLBC tumors are heterogeneous and overlap is incomplete. Breast cancers found in BRCA1 mutation carriers are also frequently triple negative and basal like. TNBC and BLBC occur most frequently in young women, especially African Americans, and tend to exhibit aggressive, metastatic behavior. These tumors respond to conventional chemotherapy but relapse more frequently than hormone receptor-positive, luminal subtypes and have a worse prognosis. New systemic therapies are urgently needed as most patients with TNBC and/or BLBC relapse with distant metastases, and hormonal therapies and HER2-targeted agents are ineffective in this group of tumors. Poly (ADP-ribose) polymerase inhibitors, angiogenesis inhibitors, EGFR-targeted agents, and src kinase and mTOR inhibitors are among the therapeutic agents being actively investigated in clinical trials in patients with TNBC and/or BRCA1-associated tumors. Increased understanding of the genetic abnormalities involved in the pathogenesis of TNBC, BLBC and BRCA1-associated tumors is opening up new therapeutic possibilities for these hard-to-treat breast cancers.

Original languageEnglish
Pages (from-to)683-692
Number of pages10
JournalNature Reviews Clinical Oncology
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 2010

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Triple-negative breast cancer: Disease entity or title of convenience?'. Together they form a unique fingerprint.

  • Cite this